At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...

ESR 在临床中应用广泛，虽然 ESR 对于疾病诊断的特异性不高，但 ESR ...